Takeda’s Zika Vaccine Candidate Fast-Tracked by FDA

Japanese drugmaker Takeda received a fast-track designation from the FDA for its Zika virus vaccine candidate, TAK-426.

The fast-track designation was given to expedite the development and review process, as there are currently no medicines or vaccines for the virus.

The candidate is currently in a Phase 1 trial under an investigational new drug application. If the results of the trial are supportive, Takeda plans to move into Phase 2 development as soon as possible.